Now showing items 1-1 of 1

    • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. 

      Kuchenbaecker, KB; Hopper, JL; Barnes, DR; Phillips, K-A; Mooij, TM; Roos-Blom, M-J; Jervis, S; van Leeuwen, FE; Milne, RL; Andrieu, N; Goldgar, DE; Terry, MB; Rookus, MA; Easton, DF; Antoniou, AC; BRCA1 and BRCA2 Cohort Consortium; McGuffog, L; Evans, DG; Barrowdale, D; Frost, D; Adlard, J; Ong, K-R; Izatt, L; Tischkowitz, M; Eeles, R; Davidson, R; Hodgson, S; Ellis, S; Nogues, C; Lasset, C; Stoppa-Lyonnet, D; Fricker, J-P; Faivre, L; Berthet, P; Hooning, MJ; van der Kolk, LE; Kets, CM; Adank, MA; John, EM; Chung, WK; Andrulis, IL; Southey, M; Daly, MB; Buys, SS; Osorio, A; Engel, C; Kast, K; Schmutzler, RK; Caldes, T; Jakubowska, A; Simard, J; Friedlander, ML; McLachlan, S-A; Machackova, E; Foretova, L; Tan, YY; Singer, CF; Olah, E; Gerdes, A-M; Arver, B; Olsson, H (2017-06-20)
      Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. Objectives: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer ...